EULAR 2023

Let's go for early treatment in axial envolvement?

Treatment opportunities and what is new in PsA

Systemic inflammation in SpA /PsA

Risk factors and prevention of arthritis

Pushing the brake with a new treatment strategy

Which is the ideal instrument to assess disease activity in axSpA?

Do NSAIDs modify the appearance of SIJ MRI?

Data from clinical studies relevant for daily practice

Should we follow chronic back pts. suspected of early axSpA?

Factors associated with remission in early peripheral spondyloarthritis

What is early axSpA?

Definition of early axSpA

Secukinumab vs Adalimumab on radiographic progression in axSpA

Clinically relevant findings for SpA detection

The effect of IL-17 inhibition on radiographic progression

Definition consensuelle ASAS de la spondyloarthrite périphérique

Effekt der IL-17 Inhibition auf die Röntgenprogression

Deberíamos seguir a los pacientes con dolor lumbar crónico con sospecha de EspAax?

Secukinumab vs Adalimumab dans la progression radiographique des SpA axiales

Daten aus klinischen Studien für die tägliche Praxis

Qual'e lo strumento ideale per la valutazione di attività di malattia nelle spondiloartriti?

Was ist frühe axSpA?

Los AINES modifican la expresión de la RM de sacrolíacas?

Klinisch wichtige Befunde zur SpA-Erkennung

Facteurs associés à l’obtention d’une rémission dans la SpA périphérique débutante

Dual inhibition of IL-17A and IL-17F: a new option in PsA

Higher comorbiditiy burden in PsA vs RA

No need of MTX again and again and...

Differences between sex and gender in PsA

MTX + Biologica in PsA

Systemic inflammation objectively detectable

Early therapy in PsA is predictive

Deucravacitinib - effective and safe

Points to consider in PsA!

Duale Inhibition A und F: neue Option für PsA

Nicht schon wieder MTX...

Frühe Therapie bei PsA prädiktiv

MTX + Biologica bei PsA

Points to consider bei PsA

Mehr Komorbiditäten bei PsA als bei RA

Deucravacitinib - effektiv und sicher

Sytemische Inflammation objektiv erkennbar

Differenze di genere nell'Artrite Psoriasi

Keeping an eye on the lung!

Putting a focus on TDM

Update on JAKi safety

Prevention - should we treat pre-arthitis?

Pushing the brake with a new treatment strategy

Preventing RA

Peresolimab - a new therapeutic principle in rheumatology?

Major adverse cardiovascular events in patients on JAK-inhibitors

The IL-23 pathway

Corticoid bridging in RA - useful and safe

Pooled safety analysis of filgotinib

Lung involvement in RA

What is new in RA?

Difficult to treat and poly-refractory RA in a clinical setting

Peresolimab - ein neues Therapieprinzip für die Rheumatologie?

Tratamiento con glucocorticoides al inicio del FAME - útil y segura!

AR difícil de tratar y polirrefractaria en la practica clinica

Kardiovaskulære hendelser hos pasienter behandlet med JAK-hemmere

Immunogenicity in Adalimumab - real-world data

Development of EMM in SpA patients treated with upadacitinib

Incidence of ILD in patients with RA and PsA

Measurement of anti-drug antibodies in rheumatology

Arthritis therapy under checkpoint-inhibition

Overview of treatment recommendations in PsA and axSpA

To stop or not to stop TNF-inhibitors after pregnancy diagnosis in women with chronic rheumatic inflammatory diseases?

Therapie der Arthritis unter Checkpoint-Inhibitoren

Desarrollo de MEM en pacientes con EspA tratados con upadacitinib

Aspetti principali delle raccomandazioni per l'Artrite Psoriasica e le Spondiloartriti

Messung von Anti-drug Antibodies in der Rheumatologie

Immunogenisitet hos pasienter behandlet med adalimumab – data fra NOR-DMARD

Interrompere o non interrompere gli anti-TNF dopo la diagnosi di gravidanza nelle donne con malattie infiammatorie reumatiche croniche?

Insidens av interstitiell lungesykdom hos pasienter med RA og PsA

Cardiovascular disease and long-term use of NSAIDs in Ankolysing Spondylitis

Childhood infections, perinatal factors, and the risk of developing Ankolysing Spondylitis

Infezioni infantili, fattori perinatali e rischio di sviluppare spondilite anchilosante

Rischio cardiovascolare e utilizzo prolungato di fans nella Spondilite anchilosante

New promising strategies in Lupus and Sjögren's Syndrome

JAK inhibition and BTK-JAK inhibition in lupus

Telitacicept in lupus

Update on CAR-T cells!

1-year data on CAR-T cell therapy in lupus

1-Jahres Daten zur CAR-T-Zell Therapie beim Lupus

Aktuelles zur CAR-T-Zelltherapie!

JAK-Inhibition und BTK-JAK-Inhibition bei Lupus

Telitacicept beim Lupus

Telitacicept in Sjögren's Syndrome

Telitacicept beim Sjögren Syndrom

IL-17 isoforms in enthesitis

COVID-19: a pandemic with a long tail

IL-17-Isoformen bei Enthesitis